CClinicalTrials.gg
Sign In
CompletedNCT07457684BONANZAUpdated Mar 9, 2026

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin

An observational study in IVF Outcomes and OVARIAN STIMULATION, sponsored by Clinique Ovo. Completed at 1 site in Canada. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Clinique Ovo · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
846
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF).

The main questions it aims to answer are:

  • Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG?
  • Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes?

Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.

02

Conditions studied

  • IVF Outcomes
  • OVARIAN STIMULATION

Keywords

  • follitropin delta
  • follitropin alfa
  • menotropins
  • IVF
03

In context

Lead sponsor

Clinique Ovo is the lead sponsor of 35 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women who underwent their first IVF cycle between 2018 and 2024 at the ovo clinic

Inclusion criteria

  • Women between 18-45 years included
  • First ovarian stimulation cycle only
  • Patients who used mixed protocols combining menotropin and follitropin alfa or delta
  • Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight.

Exclusion criteria

Exclusion Criteria:

  • Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation
  • Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators
  • Oocytes donation or fertility preservation cycles
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
846 participants (actual)
Patient registry
No

Groups and cohorts

  • Follitropin alfa (Gonal-F®) + HP-hMG (Menopur®)
  • Follitropin delta (Rekovelle®) + HP-hMG (Menopur®)
06

What researchers measure

Primary outcomes

  1. Number of utilizable blastocysts per treatment cycle

    Time frame: For IVF performed from January 2018 to December 2024

Secondary outcomes

  1. Number of stimulation days

    Time frame: For IVF performed from January 2018 to December 2024

  2. Totals doses of rFSH, HP-hMG, and FSH

    Time frame: For IVF performed from January 2018 to December 2024

  3. Costs of rFSH, HP-hMG, and FSH

    Time frame: For IVF performed from January 2018 to December 2024

  4. Number of retrieved oocytes

    Time frame: For IVF performed from January 2018 to December 2024

  5. Number of mature oocytes (MII)

    Time frame: For IVF performed from January 2018 to December 2024

  6. Number of fertilized oocytes (2PN)

    Time frame: For IVF performed from January 2018 to December 2024

  7. Total FSH/ usable blastocysts ratio

    Time frame: For IVF performed from January 2018 to December 2024

  8. Pregnancy rates

    Time frame: For IVF performed from January 2018 to December 2024

  9. Cost per blastocyst

    Time frame: For IVF performed from January 2018 to December 2024

07

Study locations

1 site
  • Clinique ovo
    Montreal, Quebec H4P 2S4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457684
Lead sponsor
Clinique Ovo
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Dec 5, 2025
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Last update
Mar 9, 2026

Study contacts

Isaac-Jacques Kadoch, MD
principal investigator · Clinique Ovo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Clinique Ovo

Start the discussion